Convalescent plasma may be of clinical benefit for treatment of 2019 Novel Coronavirus. We conducted a systematic review and meta-analysis of these interventions, including Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS-CoV) to summarize reliable evidences of the treatment.Methods:Three major electronic databases (PubMed, Google scholar) were searched，Several studies were collected for Meta-analysis.Results:Seven studies were included in Meta-analysis, including a total number of 416 patients with SARS and 169 patients with MERS infection. Meta-analysis shows that in critically ill patients, the Convalescent plasma can reduced mortality significently. (odds ratio [OR]=0.27;95% confidence interval [CI]=0.15-0.50; I2=0%;P = 0.47).Conclusions:The therapy of Convalescent plasma can reduce mortality of patients with Coronavirus，and it need to be further verified with Large-scale clinical trial.